ArticleThe Lancet regional health. Europe2022
Incidence and survival of neuroendocrine neoplasia in England 1995-2018: A retrospective, population-based study.
Article in The Lancet regional health. Europe, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Comparative Efficacy and Safety of Transarterial Therapies for Unresectable Neuroendocrine Liver Metastases: A Systematic Review.Cardiovascular and interventional radiology · 2026Pooled it
- New sights of spleen-preserving versus splenectomy in distal pancreatectomy for pancreatic neuroendocrine tumors: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Gender impact on pancreatic neuroendocrine neoplasm (PanNEN) prognosis according to survival nomograms.Endocrine · 2025Pooled it
- Impact of Sex and Deprivation on Neuroendocrine Tumour Survival: Challenges of Heterogeneous Data.Neuroendocrinology · 2025Pooled it
- Feasibility of Home Parenteral Nutrition in Patients with Intestinal Failure Due to Neuroendocrine Tumours: A Systematic Review.Nutrients · 2023Pooled it
- Metabolism of pancreatic neuroendocrine tumors: what can omics tell us?Frontiers in endocrinology · 2023Pooled it
- Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Colorectal neuroendocrine neoplasm organoids reveal the potential therapeutic value of targeting BRAF mutations.Journal of the Endocrine Society · 2026Article
- Article
- Divergent c-MYC Expression Patterns in NET and NEC: Insights from a Multicentre Cohort of 1380 Neuroendocrine Neoplasms.Endocrine pathology · 2026Article
- Pancreatic neuroendocrine tumors in patients with tuberous sclerosis: a multicenter study and systematic review.Journal of the Endocrine Society · 2026Article
- Article
- Personalizing Postoperative Surveillance: A Risk-Stratified Predictive Model for Recurrence of Gastrointestinal Neuroendocrine Neoplasms.Journal of gastrointestinal cancer · 2026Article
- Quality of life and care experiences in a US multi-institutional neuroendocrine tumor cohort.Journal of the National Cancer Institute · 2026Article
- Estimation of Future Patient Populations Eligible for Radioligand Therapies in the EU and the UK: A Modelling Study.The Lancet regional health. Europe · 2026Article
- Cancer trends in England in younger adults from 2001-2023: comparing incidence, mortality and stage at diagnosis.medRxiv : the preprint server for health sciences · 2026Article
- Breaking the Size Barrier: Endoscopic Submucosal Dissection of a Massive Flat Gastric Neuroendocrine Tumor.ACG case reports journal · 2026Article
- Incidence and Survival of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms in the Contemporary Era.JAMA network open · 2026Article
- Consensus Guideline for the Management of Peritoneal Metastases from Neuroendocrine Neoplasms.Annals of surgical oncology · 2026Article
- Triple-tracer PET (Scientific reports · 2026Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neuroendocrine neoplasia (NEN) incidence is rising internationally. We aimed to evaluate the epidemiology of NEN in England and examine changes in survival over time. Methods: A retrospective, population-based study using nationally representative data between 1995 and 2018 from the National Cancer Registry and Analysis Service (NCRAS) in England was conducted on 63,949 tumours. Age-standardized incidence was calculated using Office for National Statistics (ONS) data. Overall survival (OS) was calculated using the Kaplan-Meier estimator. Multivariable analysis was performed using an accelerated failure time model. Findings: Of 63,949 cases, 50.5% (32,309) were female. Age-adjusted incidence increased 3.7-fold between 1995 and 2018 from 2.35 to 8.61 per 100,000. In 2018, highest incidence occurred in lung (1.47 per 100,000), small intestine (1.46 per 100,000), pancreas (1.00 per 100,000) and appendix (0.95 per 100,000). In multivariable analysis, age, sex, morphology, stage, site and deprivation were independent predictors of survival ( Interpretation: NEN incidence continues to rise in England with survival improving over time. Relatively high survival compared to other cancers is an issue for long-term outcomes and funding of care. Funding: Data were extracted and transferred using a grant from Neuroendocrine cancer UK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.